carbamates has been researched along with rifampin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backman, JT; Kivistö, KT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Brophy, DF; Chittick, GE; Israel, DS; Kristoff, D; Lou, Y; Patron, R; Polk, RE; Sadler, BM; Stein, DS; Symonds, WT | 1 |
| Hatorp, V | 1 |
| Hansen, KT; Hatorp, V; Thomsen, MS | 1 |
| Bidstrup, TB; Brøsen, K; Damkier, P; Scharling, B; Stilling, N; Thomsen, MS | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Maren, K; Rojkjaer, L; Skerjanec, A; Wang, J | 1 |
| Bi, YA; El-Kattan, AF; Fahmi, OA; Goosen, TC; Lai, Y; Lam, JL; Lin, J; Rotter, CJ; Varma, MV | 1 |
| Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL | 1 |
| Brüggemann, RJ; Burger, DM; Dolton, MJ; McLachlan, AJ | 1 |
| Furihata, KI; Kusuhara, H; Maeda, K; Sugiyama, Y; Yoshikado, T | 1 |
| Asaumi, R; Imawaka, H; Kusuhara, H; Lee, W; Menzel, K; Nunoya, KI; Sugiyama, Y | 1 |
1 review(s) available for carbamates and rifampin
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacodynamics of repaglinide.
Topics: Adult; Aged; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Liver Diseases; Male; Piperidines; Renal Insufficiency; Rifampin | 2002 |
5 trial(s) available for carbamates and rifampin
| Article | Year |
|---|---|
Rifampin decreases the plasma concentrations and effects of repaglinide.
Topics: Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Mixed Function Oxygenases; Piperidines; Rifampin | 2000 |
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Biotransformation; Breath Tests; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; Drug Interactions; Erythromycin; Furans; Humans; Male; Middle Aged; Mixed Function Oxygenases; Rifabutin; Rifampin; Sulfonamides | 2001 |
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Topics: Adult; Area Under Curve; Blood Glucose; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Ketoconazole; Male; Piperidines; Rifampin; Simvastatin | 2003 |
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Carbamates; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Humans; Hydrocortisone; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Quinidine; Rifampin; Time Factors | 2004 |
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.
Topics: Adult; Anesthetics, Intravenous; Aryl Hydrocarbon Hydroxylases; Benzoates; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Deferasirox; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Iron Chelating Agents; Male; Midazolam; Piperidines; Rifampin; Triazoles | 2010 |
7 other study(ies) available for carbamates and rifampin
| Article | Year |
|---|---|
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides | 2008 |
Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
Topics: Carbamates; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Humans; Liver-Specific Organic Anion Transporter 1; Models, Theoretical; Organic Anion Transporters; Piperidines; Rifampin | 2013 |
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2014 |
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Antiemetics; Antifungal Agents; Biological Availability; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Healthy Volunteers; Humans; Metoclopramide; Nucleic Acid Synthesis Inhibitors; Organophosphates; Phenytoin; Proton Pump Inhibitors; Rifampin; Sulfonamides; Triazoles | 2014 |
Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Topics: Adult; Bosentan; Carbamates; Computer Simulation; Cytochrome P-450 CYP3A; Drug Interactions; Hepatobiliary Elimination; Humans; Itraconazole; Liver; Male; Models, Biological; Organic Anion Transporters; Pharmaceutical Preparations; Piperidines; Rifampin; Sulfonamides; Young Adult | 2017 |
Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.
Topics: Biomarkers; Carbamates; Computer Simulation; Coproporphyrins; Drug Interactions; Glyburide; Humans; Models, Biological; Organic Anion Transporters; Piperidines; Rifampin | 2019 |